Buy Biogen as stock looks ‘too good to ignore,’ Wells Fargo says

Buy Biogen as stock looks ‘too good to ignore,’ Wells Fargo says

Investors are underestimating Biogen’s Alzheimer’s drug and some of its other key businesses, according to Wells Fargo.

Post a Comment